Aimed Bio Inc. (KOSDAQ:0009K0)
South Korea
· Delayed Price · Currency is KRW
65,300
+2,500 (3.98%)
At close: Mar 6, 2026
Aimed Bio Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| Revenue | 29,651 | 11,760 | 171.21 | 111.09 |
| Revenue Growth (YoY) | 17218.10% | 6768.70% | 54.12% | - |
| Gross Profit | 29,651 | 11,760 | 171.21 | 111.09 |
| Selling, General & Admin | 20,076 | 10,704 | 5,529 | 4,922 |
| Amortization of Goodwill & Intangibles | 284.6 | 120.25 | 64.32 | 49.76 |
| Operating Expenses | 21,853 | 12,168 | 6,588 | 5,703 |
| Operating Income | 7,798 | -407.75 | -6,416 | -5,592 |
| Interest Expense | -50.81 | -93.11 | -119.08 | -123.26 |
| Interest & Investment Income | 1,462 | 1,117 | 207.22 | 162.72 |
| Currency Exchange Gain (Loss) | -522.01 | 89.94 | 7.27 | 60.6 |
| Other Non Operating Income (Expenses) | -50,780 | -4,116 | -1,617 | 11.45 |
| EBT Excluding Unusual Items | -42,092 | -3,411 | -7,938 | -5,480 |
| Gain (Loss) on Sale of Investments | -936.75 | 96.75 | -1,084 | -716.25 |
| Gain (Loss) on Sale of Assets | -0.66 | 0.66 | -7.24 | -12.95 |
| Pretax Income | -43,029 | -3,313 | -9,030 | -6,210 |
| Earnings From Continuing Operations | -43,029 | -3,313 | -9,030 | -6,210 |
| Minority Interest in Earnings | 8.65 | 9.28 | 6.95 | 41.03 |
| Net Income | -43,021 | -3,304 | -9,023 | -6,168 |
| Net Income to Common | -43,021 | -3,304 | -9,023 | -6,168 |
| Shares Outstanding (Basic) | 40 | 35 | 34 | 33 |
| Shares Outstanding (Diluted) | 40 | 35 | 34 | 33 |
| Shares Change (YoY) | 18.19% | 3.86% | 2.16% | - |
| EPS (Basic) | -1065.74 | -93.14 | -264.18 | -184.51 |
| EPS (Diluted) | -1065.74 | -93.14 | -264.18 | -184.51 |
| Free Cash Flow | 26,561 | -5,098 | -3,440 | -4,360 |
| Free Cash Flow Per Share | 657.98 | -143.71 | -100.72 | -130.42 |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Operating Margin | 26.30% | -3.47% | -3747.54% | -5033.36% |
| Profit Margin | -145.09% | -28.09% | -5269.87% | -5552.44% |
| Free Cash Flow Margin | 89.58% | -43.35% | -2009.11% | -3924.65% |
| EBITDA | 9,203 | 1,056 | -5,358 | -4,811 |
| EBITDA Margin | 31.04% | 8.98% | - | - |
| D&A For EBITDA | 1,405 | 1,464 | 1,058 | 780.45 |
| EBIT | 7,798 | -407.75 | -6,416 | -5,592 |
| EBIT Margin | 26.30% | -3.47% | - | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.